Head-to-head evidence
Dalpiciclib vs Palbociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Dalpiciclib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06009627 · Phase 2/3 · completed
The trial randomized 119 participants to an active chemotherapy comparator and used investigator masking, but it was not double-blind. Its primary endpoint was objective tumor response rate, and no primary endpoint results or statistical comparison have been posted, so the outcome cannot be judged as met or missed.
Next expected readout: October 2026 · NCT04842617 (registry estimate)
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalpiciclib's landscape · Palbociclib's landscape